S ince the composition of most peritoneal dialysis (PD) fluids is clearly nonphysiological due to low pH, hyperosmolality, and high glucose (Glu) and lactate content, it has been hypothesized that the continuous exposure of peritoneal cells to these solutions may result in an impairment of the local peritoneal host-defense mechanisms and, ultimately, in an increased risk for peritonitis. Many in vitro studies have shown adverse effects of PD solutions on various leukocyte functions (1) . In addition, several studies have identified the initial low pH of the fluids, in combination with their lactate content, as being of primary relevance. Moreover, some studies have shown the importance of hyperosmolality and excessive Glu concentrations (1) . Ex vivo studies on patients' effluent have yielded conflicting data. Peritoneal macrophages (PMΦ) isolated from effluents tested in vitro have been demonstrated to have impaired functions under different challenges. Tested at the original solution pH, all functions were demonstrated to be impaired (e.g., respiratory burst activity, phagocytosis, bacterial killing, and cytokine production and release) (2) (3) (4) . At physiological pH however, most functions normalized or were less affected (2, 3) . Glucose concentration and dwell time were also important determinants. Incubation of cells with spent dialysates resulted in a dwell timedependent reduction of cell functions, that is, the longer the dwell time of the spent dialysate had been, the better the cell functions were preserved (4, 5) .
The solution buffer also plays a role in this respect, with lactate, the conventional buffer, being clearly PDI JULY 1999 -VOL. 19 
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inferior to pyruvate on polymorphonuclear cells (PMNs) in vitro (6) and to bicarbonate on peritoneal macrophages ex vivo (7) . Furthermore, a lack of opsonization and uremic solutes was found to be of influence (8) . Thus, there is evidence showing impaired function of the peritoneal defense mechanisms during PD with Glu-based fluids. Among others, icodextrin (Ico) (a starch-based polyglucose) was developed as an alternative osmotic agent (9) . Icodextrin 7.5% is a glucose polymer of average weight (MW) 16 200 D, and a chain length varying between 4 and 250 Glu units. The osmolality of the solution is 282 mOsm/kg and the pH is 5.3. In PD patients, the daily use of Ico during the longest dwell of the day was well tolerated, safe, and effective up to 6 and 12 months, and could replace the use of hyperosmolar Glu solutions (10, 11) . Isolated PMΦs from patients treated with either Ico or Glu 2.27% for 1.5 hours resulted in better cell functions in the Ico group (12) . This observation contrasts with a study in which, after an only 15-minute dwell, the toxicity of Ico, Glu 1.36, or Glu 3.86 on mesothelial viability and functions was lost (4) . Whether the mentioned in vitro and ex vivo observations are of clinical relevance needs to be studied in prospective clinical trials. We performed a randomized prospective study in continuous cyclic peritoneal dialysis (CCPD) patients on the effect of either Glu or Ico for the long daytime dwell on ultrafiltration, safety and tolerability, and biocompatibility. The results of the peritoneal defense mechanism tests and clinical data on peritonitis are presented in this paper.
PATIENTS AND METHODS
We started an open, randomized prospective study in CCPD patients, consisting of a 2-year treatment period on either Ico-or Glu-containing solutions for the daytime dwell (14 -15 hours). All patients were allowed to use the Glu concentrations during their nighttime dwells as appropriate to their weight gain. Patients randomized to Glu could use whatever Glu concentration they needed for their daytime dwell. However, patients were advised to use as low Glu percentage as possible. Both established CCPD patients and patients new to CCPD were included. Patients had to be compliant, in a stable clinical condition (no peritonitis in the previous month), have an estimated life expectancy of more than 2 years, and be over 18 years of age. Women of childbearing potential were excluded unless taking adequate contraceptive precautions. Icodextrin was continued in case of peritonitis. We treated all peritonitis patients with intraperitoneal antibiotics, starting with gentamicin (20 mg/L once per day) and rifampin (50 mg/L every exchange), unless there was serious suspicion of a specific organism, for example in case of concomitant exit-site infection (13) . As soon as the culture results became available, antibiotics were adjusted according to culture sensitivity. The patients added the antibiotics into their dialysis solutions, including Ico. As a safety monitoring procedure, we took blood samples for maltose determination during peritonitis (14) .
The local ethics committee approved the study, and written informed consent was obtained from each patient.
Icodextrin was manufactured and supplied by ML Laboratories plc (Blaby, U.K.). It was bagged as 2 L 7.5% (w/v) by Fresenius AG, Bad Homburg, Germany. The Glu solutions were those commercially available from Baxter BV (Utrecht, The Netherlands). These were bagged as 2-L 1.36%, 2.27%, or 3.86% (w/v) solutions.
Clinic visits were made every 3 months and blood samples were taken at these visits. Unless immediately assayed, samples were stored at -70°C until use. In addition, every 3 months, dialysate samples were taken from a daytime dwell (after storage in the refrigerator by the patients) and the effluents were collected and cooled on ice until further analysis. In most patients it was necessary to collect several serial daytime dwells in order to obtain sufficient material for all the assays (see below). One patient on Glu had a "dry" day, on a visit day he made a 4-hour exchange. A 2-week difference from the clinic visit was allowed.
PHAGOCYTIC CELLS
Peritoneal macrophages were isolated from the effluents by centrifugation as previously described (15) . Final resuspensions were made in 0.1% gelatin containing Hanks balanced salt solution (GHBSS, pH 7.3; Gibco BRL, Paisley, U.K.) to a concentration of 5 × 10 6 PMΦs/mL. Total cell counts were done with a Coulter Counter ZM (Coulter Electronics Ltd, Harpenden, U.K.), and differential leukocyte counts were done on cytocentrifuge preparations stained with May-Grünwald-Giemsa (Diff-Quick, Baxter-Dade AG, Düdingen, Germany); at least 100 cells were counted. Effluents containing more than 30% PMNs were excluded and a new effluent was collected in order to prevent peritonitis-like effluents. This occurred five times during the study, one Glu patient had persistently elevated PMNs and was not left out. Mononuclear cells (MNs), used as control cells, were isolated from the buffy coat of a healthy donor using a Ficoll gradient (Pharmacia, Uppsala, Sweden). After isolation, MNs were resuspended in GHBSS at a concentration of 5 × 10 6 MNs/mL.
Peripheral blood PMNs were used to test effluent opsonic activity. The PMNs that remained after isolation of MNs from the buffy coat were purified by hypotonic shock (twice). Finally, the PMNs were resuspended in GHBSS at a concentration of 5 × 10 6 cells/mL.
BACTERIA
An isolate of coagulase-negative staphylococci (CNS; nr V10) obtained from a continuous ambulatory peritoneal dialysis (CAPD) patient with peritonitis, and a strain of Escherichia coli (ON2) were used. After incubation for 18 hours at 37°C in Mueller-Hinton broth (Difco Laboratories, Detroit, MI, U.S.A.), the suspensions were centrifuged at 2000g for 15 minutes, the supernatants discarded, and the pellets washed three times with phosphate-buffered saline (PBS). A subset of CNS, used for the phagocytosis assay, was fluorescein labeled by incubation with 500 µL 0.1 mg fluorescein 5-isothiocyanate (FITC, Sigma Chemical Co, St. Louis, MO, U.S.A.) per milliliter 0.1 mmol/L sodium carbonate buffer (pH 9.0) for 30 minutes at 37°C. Subsequent to labeling, bacteria were washed two times to remove unbound FITC, suspended in GHBSS at a concentration of 5 × 10 8 cfu/mL (16) , and stored on ice until use.
OPSONINS AND OPSONIZATION PROCEDURE
A pool of human serum (HPS), obtained from 10 healthy (HBs antigen-and HIV antibody-negative) donors and stored at -70°C, was used as the standard source of opsonins in the phagocytosis assay. Immediately prior to its use, serum was thawed and diluted in GHBSS. The CNS suspension (0.1 mL containing approximately 5 × 10 7 micro-organisms) was mixed with 0.9 mL of 5% HPS in GHBSS, and incubated in a shaking water bath for 30 minutes at 37°C. Opsonization was stopped by adding 2.5 mL ice-cold GHBSS. The suspensions were centrifuged at 3000 rpm for 15 minutes. The supernatants were discarded and the bacterial pellets resuspended in 1 mL GHBSS then stored at 4°C until use. Likewise, bacteria were incubated with the cell-free effluents from the patients to test their opsonic activity; the effluents were tested both undiluted and diluted 1:1 with GHBSS.
ASSESSMENT OF PHAGOCYTIC ACTIVITY OF PATIENTS' PERITONEAL CELLS
The uptake of HPS-preopsonized bacteria by PMΦs and donor MNs was determined in order to assess their phagocytic capacity in an assay that has been described in detail before (17) . Phagocytosis was tested by challenging the PMΦs and control MNs with labeled and opsonized CNS (see above).
Phagocytosis capacity was measured using a fluorometric phagocytosis assay, modified from Bjerknes et al. (18) and from van Strijp et al. (19) . In short, 100 µL 5 × 10 6 PMΦs or MNs/mL was suspended in 100 µL GHBSS containing 5 × 10 7 bacteria/mL, and incubated for 30 minutes at 37°C in a shaking water bath. Phagocytosis was stopped by adding 2.5 mL ice-cold PBS. After centrifugation at 1200 rpm for 5 minutes, the supernatants were discarded. To measure leukocyte-specific phagocytosis, PMΦs and MNs were labeled with anti-CD14.PE [phyco-erythrine (PE)-labeled anti-CD14; Becton Dickinson, San Jose, CA, U.S.A.]. Because anti-CD14 binds very specifically to mononuclear leukocytes, most PMΦs and MNs were colored red by PE in the FACScan. Cells were labeled by incubating the pellets at 37°C with 50 µL 4% anti-CD14.PE. After 10 minutes the cells were washed once with ice-cold PBS (pH 7.20), centrifuged at 1200 rpm for 5 minutes, decanted, and resuspended in 150 µL PBS and 150 µL 2% paraformaldehyde (Polyscience Inc., Warrington, PA, U.S.A.). The samples were analyzed in a FACStar Flow Cytometer (Becton Dickinson, Mountain View, CA, U.S.A.). Results are expressed as mean percentage of PE-and FITC-positive cells in relation to the total amount of PE positive cells. The mean intensity of fluorescence was also quantitated as a measure of the cell-adhered bacteria (expressed as a ratio).
ASSESSMENT OF EFFLUENT OPSONIC ACTIVITY
To assess the effluent opsonic activity, effluentopsonized bacteria at a final concentration of 5 × 10 7 /mL (CNS and E. coli) were likewise mixed with donor blood PMNs, and the percentage FITC-positive PMNs was determined (20) . The CNS and E. coli strains used in this experiment were labeled as described above. Non phagocyte-associated bacteria were removed by washing the cells with GHBSS three times and centrifuging them at 380g for 5 minutes. Opsonic activity is expressed as percentage FITCpositive cells. Bacteria preopsonized with 5% HPS were used as control in each experiment. 6 PMΦs or MNs/mL M199 was incubated for 24 hours with 20 µL of 10 µg/mL of lipopolysaccharide (LPS) in a moist chamber at 37°C with 7.5% CO 2 . The LPS was obtained from E. coli, strain O111-B4, as described elsewhere (23) . To test spontaneous interleukin production, another 200 µL of 5 × 10 6 PMΦs or MNs/mL was incubated for 24 hours with medium alone; MNs were used as control of the interleukin production.
After 24 hours, the tissue culture well was centrifuged for 8 minutes at 1100 rpm (248g) and supernatants were stored at -70°C until use. 
RESULTS

CLINICAL OUTCOME
Thirty-eight patients entered the study (Table 1) . At baseline no significant differences between the Glu and Ico groups were present. Duration of PD at baseline and the total follow-up in months were not different. The nightly Glu concentrations were not different between Glu and Ico users, nor did they change during the study. During follow-up an increasing number of patients were lost. The main reason for dropout was renal transplantation ( Table 2 ). The 3 patients who had to withdraw due to peritonitis (causative micro-organisms Staphylococcus aureus and Candida albicans) initially responded well to the antibiotic therapy. Two patients had combined peritonitis and exit-site infection, both restarted PD after some time. In the Glu group, 4 patients, and shortly after withdrawal a fifth patient, died. Three patients died after cardiovascular failure: 1 patient after an unexpected acute myocardial infarction at home, and 2 patients with known cardiovascular disease during a severe infection (ischemic foot ulcer and a fulminant S. aureus peritonitis). Another patient died from pancreatitis. All were male, aged 63.6 ± 2.5 years, with a PD duration of 43.1 ± 15.5 months (average ± SEM). Ultimately, 13 patients completed the full 2 years of follow-up: 6 Glu and 7 Ico users. Table 1 also shows the number of peritonitis episodes and the incidence of peritonitis in both treatment groups. Prestudy, the Glu group had a nonsignificantly higher peritonitis incidence than the Ico group, mainly due to the presence of 2 patients who had had 20 episodes. During the study, the peritonitis incidence was lower than prestudy, and the nonsignificant difference between the groups persisted. Catheter-related infectious complications during the study did not differ between the two groups: 37 exitsite infections in Glu and 32 in Ico patients, resulting in 1:8 and 1:10 months follow-up, respectively.
CELLULAR COMPOSITION
The mean duration of the daytime dwell was 14 hours 31 minutes. A total peritoneal effluent (Peff) white cell count and cell differentiations during followup are provided in Figure 1 . Total cell counts showed large intraindividual and interindividual variations (0.6 -54 × 10 6 cells) without obvious reason. There was neither a difference in total cell numbers between the two groups, nor a difference within the groups over time from baseline. The PMΦ numbers did not differ at baseline between Glu and Ico patients, but after 1 year the percentage, as well as the absolute number, of PMΦs was significantly higher in Ico patients (p < 0.05). After 2 years the percentage was still significantly higher (p = 0.009) despite the lower number of patients. The Peff percentage and absolute number of PMΦs were lower than baseline at every follow-up visit in Glu patients, being significant after 21 months, in contrast to the Ico patients. Effluent mesothelial cells did not change in absolute number, but the percentage tended to increase in Ico patients. When analyzed as differences from baseline or only the patients who completed 2 years' follow-up, no changes in the results appeared. Figure 1 also depicts the differential counts of lymphocytes, PMNs, and eosinophils in effluents. These counts did not change over time.
FUNCTIONAL ASSAYS
The phagocytic activity of CD-14-positive Peff cells for CNS tended to decrease over time in both groups (Figure 2) . At study entry, the difference in phagocytic activity between Glu and Ico patients observed was not significant. As can be seen, the phagocytic capacity decreased, albeit nonsignificantly, in both groups. The decrease was more pronounced in Glu than in Ico patients. After 1 year the difference was borderline significant between the two groups (p = 0.05, ANOVA for repeated measurements) for the uptake of opsonized CNS. The same pattern in time was seen for phagocytosis of E. coli, the difference between the groups being significant after 1-year follow-up (p < 0.05). However, after 2 years the differences in phagocytosis had disappeared. The number of cell-adhered bacteria was not different between the groups and did not change over time. The number of bacteria per CD-14-positive Peff cell was higher for E. coli than for CNS, fluctuating from 4.4 to 8.15 with E. coli and 3.6 to 5.9 with CNS.
The oxidative metabolic response of Peff cells of Glu patients was not different from that of Ico pa- tients, and did not change over time. As can be seen in Table 3 , the variation was large; at only a single point during follow-up (at 6 months) was there a difference between the two groups that reached statistical significance.
In contrast, the opsonic capacity of effluent for CNS was rather stable during follow-up in both Glu and Ico patients, fluctuating from 71.3% to 79.7%. The opsonic capacity for E. coli was significantly lower, but was also stable over time and also did not differ between the two groups (from 20.1% to 40.8%, Table 3 ). Again, a large variation within and between the two patient groups was seen. In the 1:1 diluted effluents, the opsonic capacity was lower than in undiluted effluents, for E. coli more so than for CNS (range 16.6% -30.3% and 62% -75.3%, respectively, data not shown in Table 3 ).
CYTOKINE PRODUCTION
The ability of Peff cells to produce proinflammatory cytokines was measured repeatedly throughout the study. Again, a large interindividual and intraindividual variation in cytokine levels was seen for all cytokines (Table 4 ) except for TGFβ. Incubated in vitro, the TGFβ concentrations in the supernatants of Peff cells remained below the detection limit of the assay in a large majority of cases. When measured directly in effluents, no signals of any significance were obtained, not even in effluents that had been concentrated tenfold prior to testing. We expressed the in vitro cytokine results for IL-1β, TNFα, and IL-6 as a ratio of stimulated over nonstimulated values at baseline and after 1-year follow-up (9 -15 months). Neither the absolute values nor these ratios reached statistical significance when data from Glu and Ico patients were compared, except the ratio IL-6 (Table 4) . When tested against the baseline value all results were not significantly different.
DISCUSSION
In this study of Ico in CCPD, we evaluated the peritoneal defenses during long-term follow-up and related them to the clinical course of these patients. In this paper we focused on the cells and opsonins present in the patients' effluents. Twenty-four patients completed 1 year's and 13 patients completed 2 years' follow-up. This level of censoring somewhat hampers the interpretation of our statistical analyses. During the study we did not observe a difference between the groups in the incidence of PD-related infections. The decrease in peritonitis incidence over time is probably attributable to connection improvement in the prestudy period (from CAPD spike system to CAPD Y-set and CCPD, Baxter). The average age and the PD duration of the patients who died were higher than in the total study population. We have no clinical or laboratory evidence that the deaths of these patients were somehow caused by or related to their use of Glu-based dialysis fluids.
The total number of cells and differential counts we found in Peff were in accordance with the values reported in the literature (24) . The large intrapatient and interpatient variations in the differential counts and absolute cell counts makes it difficult to draw firm conclusions. However, the PMΦ fraction in the differential counts and their absolute number decreased over time on dialysis, and did so significantly more in Glu than in Ico patients. Earlier, this pattern was shown during the first year of treatment only in a high peritonitis-incidence subgroup of CAPD patients (25) . The mesothelial cell fraction in the differential counts tended to increase in Ico patients from baseline, while their absolute number did not change. A correlation between a low number of mesothelial cells in the Peff and a high peritonitis incidence has been described (26) . The presence of mesothelial cells might reflect the turnover rate of the mesothelium, and a regenerating mesothelium could play a role in preventing peritonitis. On the other hand, high numbers of mesothelial cells might also reflect irritation of the mesothelial membrane, and in that case it would be an unfavorable sign. In our study, no relation between the presence of mesothelial cells in the differential counts and peritonitis incidence was found. The complement-dependent phagocytosis of E. coli and the IgG-dependent phagocytosis of CNS both decreased over time, but in Glu patients more than in Ico patients. The PMΦ oxidative metabolic response, as measured by chemiluminescence, did not change over time and neither did it differ between the groups. Our results seem to support the previous ex vivo experiments in which the phagocytic capacity of PMΦs after a 4-hour dwell was better in Ico patients than in Glu patients (12) . The opsonic capacity of patients' effluent was stable, as was the Peff cells ability to produce cytokines. IL-1β and IL-6 tended to decrease over time, but the variation in measured values was of such a magnitude that no distinct pattern could be discerned.
In contrast to the previous in vitro studies and ex vivo observations, we were thus not able to establish a significant difference in favor of or against the use of Ico. Important clinical end points including peritonitis, and exit-site infection rates, as a reflection of an impaired peritoneal defense, did not differ between the groups.
In summary, this long-term clinical study did provide evidence that the routine use of a novel PD solution containing icodextrin did not deteriorate peritoneal defense determinants more than glucose, and maybe icodextrin had a positive effect on some aspects of the peritoneal defense system. Moreover, there is no indication for a different peritonitis incidence in this icodextrin group of CCPD patients. This finding, in combination with previously reported increases in ultrafiltration on icodextrin, suggests that icodextrin is an important addition to the range of osmotic agents that can be applied to PD (10, 11) .
